Table 1.
Patient and tumor characteristics (n = 385)
| n (% of total) | |
|---|---|
| Sex | |
| Male | 112 (29.1) |
| Female | 273 (70.1) |
| Age, y | |
| Median | 62 |
| Range | 29-88 |
| HIV | |
| Positive | 16 (4.2) |
| Negative | 220 (57.1) |
| Not tested | 149 (38.7) |
| Performance status | |
| 0 | 212 (55.1) |
| 1 | 141 (36.6) |
| 2 | 19 (4.9) |
| 3 | 6 (1.6) |
| Not documented | 7 (1.8) |
| T stage | |
| Tx | 1 (0.3) |
| T1 | 46 (11.9) |
| T2 | 174 (45.2) |
| T3 | 92 (23.9) |
| T4 | 72 (18.7) |
| N stage (TNM 7) | |
| Nx | 1 (0.3) |
| N0 | 185 (48.1) |
| N1 | 72 (18.7) |
| N2 | 66 (17.1) |
| N3 | 61 (15.8) |
| N stage (TNM 8) | |
| Nx | 1 (0.3) |
| N0 | 185 (48.1) |
| N1a | 168 (43.6) |
| N1b | 1 (0.3) |
| N1c | 30 (7.8) |
| M stage | |
| Mx | 3 (0.8) |
| M0 | 382 (99.2) |
| Stage grouping (TNM 7&8) | |
| 1 | 38 (9.8) |
| 2 | 124 (32.2) |
| 3 | 221 (57.4) |
| x | 2 (0.5) |
| Radiation therapy | |
| Temporarily interrupted∗ | 12 (3.1) |
| Prematurely stopped† | 8 (2.1) |
| Delivered as planned | 365 (94.8) |
| Chemotherapy interrupted or stopped | |
| Yes | 41 (10.9‡) |
| No | 335 (89.1‡) |
∗
Radiation therapy was subsequently continued to full dose.
†
Total dose not delivered.
‡
Percentage of total number of patients who had chemotherapy (n = 376).